CA3130580A1 - Compositions and methods for treatment of depression and other disorders - Google Patents

Compositions and methods for treatment of depression and other disorders Download PDF

Info

Publication number
CA3130580A1
CA3130580A1 CA3130580A CA3130580A CA3130580A1 CA 3130580 A1 CA3130580 A1 CA 3130580A1 CA 3130580 A CA3130580 A CA 3130580A CA 3130580 A CA3130580 A CA 3130580A CA 3130580 A1 CA3130580 A1 CA 3130580A1
Authority
CA
Canada
Prior art keywords
nri
maoi
aspects
hours
phenelzine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3130580A
Other languages
English (en)
French (fr)
Inventor
Magid Abraham
Ken GILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuraWell Therapeutics Inc
Original Assignee
NeuraWell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuraWell Therapeutics Inc filed Critical NeuraWell Therapeutics Inc
Publication of CA3130580A1 publication Critical patent/CA3130580A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA3130580A 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders Pending CA3130580A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806831P 2019-02-17 2019-02-17
US62/806,831 2019-02-17
PCT/US2020/018567 WO2020168337A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Publications (1)

Publication Number Publication Date
CA3130580A1 true CA3130580A1 (en) 2020-08-20

Family

ID=72045151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3130580A Pending CA3130580A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Country Status (7)

Country Link
US (1) US12465611B2 (https=)
EP (1) EP3923919A4 (https=)
JP (1) JP2022521208A (https=)
CN (1) CN113631157A (https=)
AU (2) AU2020223284A1 (https=)
CA (1) CA3130580A1 (https=)
WO (1) WO2020168337A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727545A2 (en) * 2023-06-16 2026-04-22 Neurawell Therapeutics Combination treatments for depression and other disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
WO2005102366A2 (en) 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20090054489A1 (en) 2005-02-23 2009-02-26 Prexa Pharmaceuticals, Inc. Multimediator Dopamine Transport Inhibitors, and Uses Related Thereto
CA2598838A1 (en) 2005-02-23 2006-08-31 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
EP2258382A3 (en) 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
CN101203505A (zh) 2005-04-22 2008-06-18 惠氏公司 苯并二氢吡喃和苯并吡喃衍生物及其用途
MX2007012882A (es) 2005-04-22 2007-12-10 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion.
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
CN101657193A (zh) * 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
PL2560624T3 (pl) * 2010-04-23 2019-01-31 Kempharm, Inc. Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
US20130324609A1 (en) 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
US20130217673A1 (en) 2012-02-22 2013-08-22 Warsaw Orthopedic, Inc Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
PE20141906A1 (es) * 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US10624939B2 (en) 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN111233737B (zh) 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Also Published As

Publication number Publication date
WO2020168337A4 (en) 2020-10-08
JP2022521208A (ja) 2022-04-06
EP3923919A4 (en) 2022-12-07
AU2020223284A1 (en) 2021-09-16
EP3923919A1 (en) 2021-12-22
US12465611B2 (en) 2025-11-11
AU2023226657A1 (en) 2023-09-21
WO2020168337A1 (en) 2020-08-20
US20220117975A1 (en) 2022-04-21
CN113631157A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
Kessler et al. Mood disorders: Bipolar and major depressive disorders
Cheer et al. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness
CN107849021A (zh) 治疗炎症或神经性疼痛的方法
TWI428130B (zh) 治療急性躁狂症之藥學組成物及方法
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
TW202313003A (zh) 用於治療憂鬱之組成物及方法
KR20240152410A (ko) 아티카프란트를 포함하는 조성물
US20220168286A1 (en) Treatment of raynaud&#39;s disease
JP2009515952A (ja) 制御放出性製剤のクエチアピン
AU2023226657A1 (en) Compositions and methods for treatment of depression and other disorders
Gentile Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions
WO2024102346A9 (en) Methods of treating eye pain and eye disorders
TW200916091A (en) Neramexane for the treatment of nystagmus
Naqvi Pharmacotherapy of obesity weight loss maintenance and risk reduction
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson&#39;s disease, or parkinson&#39;s disease motor disability using befiradol
US20240398771A1 (en) Treatment of scleroderma and raynaud&#39;s syndrome
Tablets et al. PrZOLMITRIPTAN ODT
JP7852200B2 (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
Capsule Summary of Product Characteristics
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for
WO2026085331A1 (en) Mefluleucin for use in the treatment of suicidal ideations associated with depression
HK40061449A (en) Methods of treating inflammation or neuropathic pain
Bajorek et al. Adverse reactions to medication
Krasuski Dr. Jack’s MedQuik Guide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210817

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240712

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401